PTP4A3 and cancer: As a result, targeting PRL3 presents an important therapeutic strategy in the context of cancer treatment, as evidenced by recent clinical trials using PRL3-zumab, the first-in-class humanized antibody targeting intracellular PRL3 35, 36.